Literature DB >> 28888416

Toll Like Receptors in systemic sclerosis: An emerging target.

Steven O'Reilly1.   

Abstract

Pattern Recognition Receptors are critical receptors that elicit an immune response upon their activation that culminates in activation of NF-KB and cytokine secretion. Key among these receptors are the Toll-Like Receptors (TLRs). These evolutionary conserved receptors form a key part in the defence against various pathogens and comprise a key part of the innate immune system. Systemic sclerosis is an autoimmune disease in which a breach of tolerance has occurred and leads to fulminant autoimmunity, dysregulated cytokines, pro-fibrotic mediators and activation of fibroblasts leading to fibrosis via collagen deposition. It has become apparent in recent years that the innate immune system and specifically TLRs are important in disease pathogenesis; responding to internal ligands to initiate an innate immune response ultimately leading to release of a variety of factors that initiate and perpetuate fibrosis. This review will examine the recent evidence of TLR signalling in systemic sclerosis and the internal danger associated molecules that may mediate the fibrotic cascade. Evaluation of their contribution to disease in systemic sclerosis and possible therapeutic targeting will be discussed.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrosis; Immunity; Innate; Macrophages; Methylation; Myofibroblast; Systemic sclerosis; TLR

Mesh:

Substances:

Year:  2017        PMID: 28888416     DOI: 10.1016/j.imlet.2017.09.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  13 in total

1.  The Immunogenetics of Systemic Sclerosis.

Authors:  Begüm Ünlü; Ümit Türsen; Zeynab Rajabi; Navid Jabalameli; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Fibronectin-EDA accumulates via reduced ubiquitination downstream of Toll-like receptor 9 activation in SSc-ILD fibroblasts.

Authors:  Ferhan Tuncer; Melissa Bulik; John Villandre; Travis Lear; Yanwen Chen; Beyza Tuncer; Daniel J Kass; Eleanor Valenzi; Christina Morse; John Sembrat; Robert Lafyatis; Bill Chen; John Evankovich
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-08-23       Impact factor: 6.011

Review 3.  Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors:  L Frasca; R Lande
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

4.  Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.

Authors:  Roberto Lande; Anna Mennella; Raffaella Palazzo; Immacolata Pietraforte; Katia Stefanantoni; Nicoletta Iannace; Alessia Butera; Monica Boirivant; Roberta Pica; Curdin Conrad; Carlo Chizzolini; Valeria Riccieri; Loredana Frasca
Journal:  Int J Mol Sci       Date:  2020-07-19       Impact factor: 5.923

5.  CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.

Authors:  Roberto Lande; Ernest Y Lee; Raffaella Palazzo; Barbara Marinari; Immacolata Pietraforte; Giancarlo Santiago Santos; Yves Mattenberger; Francesca Spadaro; Katia Stefanantoni; Nicoletta Iannace; Aleksandra Maria Dufour; Mario Falchi; Manuela Bianco; Elisabetta Botti; Luca Bianchi; Montserrat Alvarez; Valeria Riccieri; Marie-Elise Truchetet; Gerard C L Wong; Carlo Chizzolini; Loredana Frasca
Journal:  Nat Commun       Date:  2019-05-01       Impact factor: 14.919

6.  Alternatively activated macrophages are associated with the α2AP production that occurs with the development of dermal fibrosis : The role of alternatively activated macrophages on the development of fibrosis.

Authors:  Yosuke Kanno; En Shu; Hirofumi Niwa; Hiroyuki Kanoh; Mariko Seishima
Journal:  Arthritis Res Ther       Date:  2020-04-10       Impact factor: 5.156

Review 7.  Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.

Authors:  Kumar Vijay
Journal:  Int Immunopharmacol       Date:  2018-05-04       Impact factor: 4.932

Review 8.  Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair.

Authors:  Michaël Schreurs; C Maarten Suttorp; Henricus A M Mutsaers; Anne Marie Kuijpers-Jagtman; Johannes W Von den Hoff; Edwin M Ongkosuwito; Paola L Carvajal Monroy; Frank A D T G Wagener
Journal:  Med Res Rev       Date:  2019-05-18       Impact factor: 12.944

9.  Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.

Authors:  Elena Raschi; Daniela Privitera; Caterina Bodio; Paola Adele Lonati; Maria Orietta Borghi; Francesca Ingegnoli; Pier Luigi Meroni; Cecilia Beatrice Chighizola
Journal:  Arthritis Res Ther       Date:  2020-11-09       Impact factor: 5.156

10.  Parvovirus B19 activates in vitro normal human dermal fibroblasts: a possible implication in skin fibrosis and systemic sclerosis.

Authors:  Rosaria Arvia; Francesca Margheri; Maria A Stincarelli; Anna Laurenzana; Gabriella Fibbi; Giorgio Gallinella; Clodoveo Ferri; Mario Del Rosso; Krystyna Zakrzewska
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.